Long-term effects of somatostatin therapy in acromegaly
Author Information
Author(s): Maiza Jean Christophe, Vezzosi Delphine, Matta Maria, Donadille Florence, Loubes-Lacroix Florence, Cournot Maxime, Bennet Antoine, Caron Philippe
Primary Institution: Department of Endocrinology, CHU Rangueil Toulouse, France
Hypothesis
To evaluate the antihormonal and antitumour efficacy of long-term primary treatment with somatostatin analogues in patients with GH-secreting pituitary adenoma responsive to SSTa.
Conclusion
Long-term treatment with somatostatin analogues is effective in controlling hormone levels and reducing tumor size in acromegalic patients.
Supporting Evidence
- After 1 year, mean GH and IGF-1 levels significantly decreased.
- 70% of patients achieved GH levels below 2 µg/l after treatment.
- 43% mean reduction in tumor size was observed.
Takeaway
This study shows that a medicine called somatostatin can help people with a certain type of tumor by lowering their hormone levels and shrinking the tumor over many years.
Methodology
An open, prospective, single-centre clinical study monitoring patients treated with SSTa for a mean duration of 8 years.
Limitations
The study was conducted at a single center, which may limit the generalizability of the results.
Participant Demographics
The cohort included 17 men and 19 women with a mean age of 53 ± 2.5 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website